# Phase II Study of Durvalumab(MEDI4736) + Tremelimumab in Pulmonary Sarcomatoid Carcinoma

> **NCT06446570** · PHASE2 · COMPLETED · sponsor: **Seoul National University Hospital** · enrollment: 18 (actual)

## Conditions studied

- HNSCC
- Head and Neck Neoplasms

## Interventions

- **DRUG:** Durvalumab,Tremelimumab

## Key facts

- **NCT ID:** NCT06446570
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-10
- **Primary completion:** 2019-02-22
- **Final completion:** 2021-06-03
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2024-06-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06446570

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06446570, "Phase II Study of Durvalumab(MEDI4736) + Tremelimumab in Pulmonary Sarcomatoid Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06446570. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*